NDAINJECTIONINJECTABLE
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
OMNIPAQUE 140 (iohexol) by GE HealthCare is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 1985.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMNIPAQUE 140 (iohexol) is a non-ionic, water-soluble radiographic contrast agent indicated for X-ray imaging procedures. It is administered by injection to enhance visualization of internal body structures during diagnostic radiography. The drug works by increasing radiodensity in targeted anatomical regions, enabling clearer imaging for clinical diagnosis.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); brand teams should expect portfolio rationalization and resource reallocation toward pipeline assets.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Clinical Trials (4)
Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection
Started Apr 2019
24 enrolled
Contrast-induced NephropathyCoronary Angiography
A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants
Started Aug 2016
40 enrolled
Healthy
Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles
Started Feb 2013
84 enrolled
Colorectal Neoplasms
A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
Started Oct 2010
38 enrolled
Infections, Human Immunodeficiency Virus and Tuberculosis
Worked on OMNIPAQUE 140 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.